Recently, the list for the 2025 Shanghai "Oriental Talent Program" Top-Tier Project (Science and Technology Platform) was officially announced. Dr. Wan Yakun, founder, chairman, and CEO of Novamab was successfully selected due to his systematic innovation capabilities in critical core technologies for VHH-based innovative drugs and his breakthrough achievements in industrialization.

As the leader of a biopharmaceutical company focused on the research and development of innovative VHH drugs, Dr. Wan Yakun has long adhered to the guidance of technological innovation and clinical value, leading the team to continuously break through key technical difficulties such as VHH engineering, innovative drug delivery methods, and industrial transformation, and building a core technology system with independent intellectual property rights. As of now, the company has applied for more than 90 invention patents, with 35 authorized, and led 10 national and provincial/ministerial-level  key projects.

In terms of R&D pipeline, Novamab has achieved commercialization of 1 product, advanced 2 projects into clinical stages, and obtained four clinical approvals, covering multiple areas with significant unmet clinical needs such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD), etc.

Previously selected for talent programs including "Zhangjiang Outstanding Talent" and "Pudong New Area Pearl Program Leading Talent," Dr. Wan Yakun's inclusion in the Shanghai "Oriental Talent Program" further recognizes his sustained contributions to breakthroughs in key core technologies and the industrialization of scientific achievements, while also highlighting Novamab's innovative strength and development potential in the cutting-edge biopharmaceutical field.

About the Oriental Talent Program

The "Oriental Talent Program" is the highest level and comprehensive talent project launched by the Shanghai Municipal Party Committee and Government in 2023 after integrating and optimizing various existing talent programs. It aims to create a complete team covering strategic scientists to outstanding young talents, and provide strong intellectual support and talent guarantee for accelerating the construction of a socialist modern international metropolis with global influence. The program sets up six sub projects: team, leadership, entrepreneurship, teachers, top-notch, and youth. Among them, the "top-notch project" focuses on basic cutting-edge and key core technology fields, selects top-notch talents who play core roles in innovative research, and represents the highest support and recognition of high-level talents in Shanghai.

About Novamab

Novamab, located in Shanghai International Medical Park (Pudong New Area), is an innovative biopharmaceutical company in the clinical stage, focusing on the development of (VHH drugs for the billion dollars respiratory and inflammatory disease markets. Our mission is to provide patients with life-changing treatment options through the development of innovative VHH drugs, while striving to improve the efficacy and medication convinience.

The company fully adopts the advantages of VHH to build highly differentiated VHH drug platforms, including inhalable VHH platform (Aerobody), oral VHH platform (Orabody), and Bi/multi VHH platform (Pluribody). The product pipeline covers FIC Phase II inhaled IL-4Rα VHH, Phase I inhaled TSLP VHH, as well as multiple TL1A targeted bi/multiple VHH and oral VHH pipelines. Indications include asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD).

Novamab is committed to providing more efficient, safe, and convenient treatment options for patients worldwide through innovative VHH drugs.

For detailed information, please visit www.novamab.com

 https://www.linkedin.com/company/89624539/admin/dashboard/